FTC Closes Antitrust Probe Of Allergan's Acular Drug

Law360, New York (February 13, 2004, 12:00 AM EST) -- The Federal Trade Commission has officially closed its antitrust investigation into accusations that Allergan tried to block generic competition for its Acular eye drug.

The FTC's Bureau of Competition wrapped up its probe after the U.S. District Court for the Northern District of California ruled in December that the patent covering the top-selling anti-inflammatory treatment is valid and enforceable.

The district court ruled that Apotex and some of its subsidiaries would infringe on the Acular patent by producing a proposed generic version. The antitrust action was...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.